This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Capricor Therapeutics (CAPR) Reports Q3 Loss, Lags Revenue Estimates
by Zacks Equity Research
Capricor (CAPR) delivered earnings and revenue surprises of 38.57% and -35.46%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?
CHF Solutions System to be Used in JAHVH Study After Final Nod
by Zacks Equity Research
CHF Solutions' (CHFS) Aquadex system to be used for the outpatient study on heart failure, conducted by James A. Haley Veterans' Hospital and Clinics. The study receives final approval.
Zynex (ZYXI) Scales 52-Week High: What's Driving the Stock?
by Zacks Equity Research
Zynex (ZYXI) is likely to maintain the current high on a number of favorable factors.
Abbott (ABT) Gets FDA Nod for Spinal Cord Stimulation System
by Zacks Equity Research
Abbott (ABT) is upbeat about the latest clearance in its neuromodulation product portfolio.
Align Gains on Innovation Despite Poor Case Shipment in China
by Zacks Equity Research
Align Technology (ALGN) succeeds in consecutively delivering a solid spurt in Invisalign Technology volumes across the company's entire clientele.
Natera (NTRA) Scales 52-Week High: What's Driving the Stock?
by Zacks Equity Research
Natera (NTRA) is likely to maintain the current high on a number of favorable factors.
Illumina (ILMN) Inks Deal to Develop Distributable Test Kits
by Zacks Equity Research
Illumina (ILMN) aims to expand access to genomic-based testing and improve patient outcome through the new partnership deal.
FDA Nods to Medtronic's (MDT) New Age Evolut PRO+ TAVR
by Zacks Equity Research
This latest FDA approval of Medtronic's (MDT) Evolut PRO+ follows the last month's nod from the regulatory body for the Evolut TAVR system with regard to expanded indication.
Insulet Receives FDA Approval for ACE Pump Implementation
by Zacks Equity Research
FDA's approval will enable Insulet (PODD) to boost its insulin management business.
Bruker (BRKR) Enters Into Alliance With Murdoch University
by Zacks Equity Research
Bruker's (BRKR) collaboration with Murdoch University will support International Centre of Excellence in metabolic phenotyping.
Neogen Forms Partnership With IGS to Enhance Beef Profile
by Zacks Equity Research
Neogen (NEOG), through the IGS partnership, aims to help cattle producers choose better cattle and enhance their productivity.
Medtronic Receives European Nod for Glucose Monitoring System
by Zacks Equity Research
Medtronic (MDT) plans to upgrade diabetes care by combining technical advancement with better user experience.
Abbott Partners With Sanofi to Upgrade Diabetes Management
by Zacks Equity Research
Abbott (ABT) collaborates with Sanofi to revolutionize diabetes care through technological advancements.
Baxter's (BAX) Cheetah Acquisition to Aid Patient Monitoring
by Zacks Equity Research
Baxter (BAX) expects this deal to remain neutral to its earnings in 2019 and 2020.
Neogen Gets AOAC Validation for NeoSeek to Ensure Food Safety
by Zacks Equity Research
Neogen's (NEOG) proprietary testing platform gets upgraded to reduce the incidence of bacterial contamination in livestock.
NuVasive's New TLIF Implant Broadens Spine Surgery Option
by Zacks Equity Research
NuVasive's (NUVA) Modulus TLIF-A is designed to work smoothly with the existing MAS TLIF and MAS Midline access systems.
Boston Scientific's (BSX) Vercise Gevia DBS Gets FDA Nod
by Zacks Equity Research
Boston Scientific's (BSX) Vercise Gevia DBS system should boost neuromodulation revenues for the company.
Capricor Therapeutics (CAPR) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Capricor (CAPR) delivered earnings and revenue surprises of 26.25% and 86.36%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
Will Capricor Therapeutics (CAPR) Report Negative Q2 Earnings? What You Should Know
by Zacks Equity Research
Capricor (CAPR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Capricor Therapeutics (CAPR) Reports Q1 Loss, Lags Revenue Estimates
by Zacks Equity Research
Capricor (CAPR) delivered earnings and revenue surprises of 27.27% and -42.25%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?
Capricor Therapeutics (CAPR) Reports Q3 Loss, Lags Revenue Estimates
by Zacks Equity Research
Capricor (CAPR) delivered earnings and revenue surprises of -7.69% and -75.67%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
Analysts Estimate Capricor Therapeutics (CAPR) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Capricor (CAPR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Capricor Therapeutics (CAPR) Reports Q2 Loss, Misses Revenue Estimates
by Zacks Equity Research
Capricor (CAPR) delivered earnings and revenue surprises of -7.69% and -1.46%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?
Capricor Therapeutics (CAPR) Looks Good: Stock Adds 13.9% in Session
by Zacks Equity Research
Capricor Therapeutics (CAPR) was a big mover last session, as the company saw its shares rise almost 14% on the day amid huge volumes.
Rockwell Medical (RMTI) Looks Good: Stock Moves 5.9% Higher
by Zacks Equity Research
Rockwell Medical, Inc. (RMTI) shares rose almost 6% in the last trading session.